Plain-English translation of NCT06388720 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment approach for people with high-risk bladder cancer whose cancer did not respond to BCG, the standard first-line treatment. The study uses two chemotherapy medications— and —given as injections directly into the bladder in a sequential pattern (one after the other). Researchers want to see if this combination can prevent the cancer from coming back and help patients avoid bladder removal surgery.
When bladder cancer doesn't respond to BCG treatment, patients typically face the option of having their entire bladder removed—a major surgery with lasting life changes. This trial exists to find an alternative, less invasive option that might control high-risk cancers without removing the bladder.
You likely qualify if…
You likely don't qualify if…
You would receive sequential bladder injections of the two study medications on a defined treatment schedule. The treatment is delivered directly into your bladder during a procedure, which means you would have multiple clinic visits over the study period. Your doctors will monitor you closely with follow-up cystoscopy exams (camera studies of the bladder), imaging scans, and blood tests to check how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
South Korea
Phase
Testing effectiveness
Sponsor
National Cancer Center, Korea
Collaborators
Korea University Anam Hospital, Pusan National University Hospital
Enrollment target
~82 participants
Started
November 2024
Primary completion
December 2027
Age range
20 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ho Kyung Seo, MD
National Cancer Center, Korea
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.